In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. 

We share the stories of a select few 2024 Fierce 50 honorees and interesting highlights from this year's special report. 

To learn more about the topics in this episode: 


Fierce 50 of 2024 


Innovation Honorees


Health Equity Honorees


Social Impact Honorees


Breakthroughs Honorees
Patient Advocacy Honorees

In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. 
We share the stories of a select few 2024 Fierce 50 honorees and interesting highlights from this year's special report. 
To learn more about the topics in this episode: 
<ul>
<li>
<a href="https://www.fiercepharma.com/collection/fierce-50-2024">Fierce 50 of 2024 </a>
</li>
<li>
<a href="https://www.fiercepharma.com/book/innovation">Innovation Honorees</a>
</li>
<li>
<a href="https://www.fiercepharma.com/book/health-equity">Health Equity Honorees</a>
</li>
<li>
<a href="https://www.fiercepharma.com/book/social-impact">Social Impact Honorees</a>
</li>
<li>
<a href="https://www.fiercepharma.com/book/breakthroughs">Breakthroughs Honorees</a>
</li>
<li><a href="https://www.fiercepharma.com/book/patient-advocacy">Patient Advocacy Honorees</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

A closer look at the Fierce 50

In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. 

Fierce Pharma’s Zoey Becker chats with Stefan Merlo, vice president of commercial operations, North America at CSL Seqirus. He discusses the company's differentiated flu vaccine portfolio and how its manufacturing process has evolved over the decades to create and distribute vaccines offering targeted protection each year.

To learn more about the topics in this episode: 
Driving flu vaccine uptake in the post-pandemic era
Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season

In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. 
Fierce Pharma’s Zoey Becker chats with Stefan Merlo, vice president of commercial operations, North America at CSL Seqirus. He discusses the company's differentiated flu vaccine portfolio and how its manufacturing process has evolved over the decades to create and distribute vaccines offering targeted protection each year.
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/driving-flu-vaccine-uptake-post-pandemic-era">Driving flu vaccine uptake in the post-pandemic era</a></li>
<li><a href="https://www.fiercepharma.com/pharma/flu-vaccine-makers-csl-seqirus-sanofi-and-gsk-kick-initial-shipments-ahead-upcoming">Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season</a></li>
</ul>

A look at flu vaccine manufacturing and supply in the post-pandemic era

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond. 

Fierce Pharma’s Zoey Becker chats with Gregg Sylvester, M.D., Chief Health Officer at CSL Seqirus, to get insight on what we might expect to see from this upcoming flu season. He also explains efforts to increase vaccine uptake through awareness and education campaigns.  

To learn more about the topics in this episode: 
Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season
CDC starts 'Wild to Mild' campaign to reverse falling flu vaccine use in key groups
American Lung Association, Sanofi urge high-risk communities to grab their flu shots in 'United Against Flu' campaign

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond. 
Fierce Pharma’s Zoey Becker chats with Gregg Sylvester, M.D., Chief Health Officer at CSL Seqirus, to get insight on what we might expect to see from this upcoming flu season. He also explains efforts to increase vaccine uptake through awareness and education campaigns.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/flu-vaccine-makers-csl-seqirus-sanofi-and-gsk-kick-initial-shipments-ahead-upcoming">Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season</a></li>
<li><a href="https://www.fiercepharma.com/pharma/cdc-starts-wild-mild-campaign-reverse-falling-flu-vaccine-use-key-groups">CDC starts 'Wild to Mild' campaign to reverse falling flu vaccine use in key groups</a></li>
<li><a href="https://www.fiercepharma.com/marketing/american-lung-association-sanofi-urge-high-risk-communities-grab-their-flu-shots-its">American Lung Association, Sanofi urge high-risk communities to grab their flu shots in 'United Against Flu' campaign</a></li>
</ul>

Driving flu vaccine uptake in the post-pandemic era

Biotherapeutics are transforming healthcare for over 350 million patients globally, tackling everything from cancer and diabetes to rare diseases.

Human embryonic kidney (HEK) 293 cells play a key role in the manufacturing of many of these life-changing products. However, they are not without their challenges.

In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani, Global Product Manager at Digital Biology Group, discusses the critical need to accurately quantify HEK293 DNA in biotherapeutics to ensure patient safety and regulatory compliance.

Gurnani highlights the risks of residual DNA integrating into a patient's genome, potentially causing cancer or genetic abnormalities. She also addresses the limitations of traditional quantification methods like qPCR, which can be time-consuming and prone to errors.

We also look at some key innovations in the field, such as Bio-Rad’s Vericheck ddPCR HEK293 Residual DNA Quantification Kit that can minimize false positives by specifically targeting HEK293 DNA.

For deeper insights into these challenges and innovations, listen to the full episode.

Biotherapeutics are transforming healthcare for over 350 million patients globally, tackling everything from cancer and diabetes to rare diseases.
Human embryonic kidney (HEK) 293 cells play a key role in the manufacturing of many of these life-changing products. However, they are not without their challenges.
In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani, Global Product Manager at Digital Biology Group, discusses the critical need to accurately quantify HEK293 DNA in biotherapeutics to ensure patient safety and regulatory compliance.
Gurnani highlights the risks of residual DNA integrating into a patient's genome, potentially causing cancer or genetic abnormalities. She also addresses the limitations of traditional quantification methods like qPCR, which can be time-consuming and prone to errors.
We also look at some key innovations in the field, such as Bio-Rad’s Vericheck ddPCR HEK293 Residual DNA Quantification Kit that can minimize false positives by specifically targeting HEK293 DNA.
For deeper insights into these challenges and innovations, listen to the full episode.

In this episode sponsored by Bio-Rad, Dipika Gurnani of Digital Biology Group outlines the challenges and innovations for quantifying HEK 293 DNA.

A closer look at the Fierce 50

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips